BiotechTube
Telo Therapeutics

Telo Therapeutics

San Francisco, United States· Est.
telotherapeutics.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $8M

Overview

Telo Therapeutics is a private, preclinical-stage biotech focused on oncology, leveraging targeted protein degradation to enhance nuclear transport inhibition. Its lead candidate, TSM74, is a novel, orally bioavailable degrader of XPO1 designed to overcome the toxicity limitations of existing covalent inhibitors. The company is incubated at MBC Biolabs and has received support from investors like the MIF and recognition such as a Servier Golden Ticket, positioning it to advance its pipeline for solid and hematological malignancies.

Oncology

Technology Platform

Platform for developing orally bioavailable targeted protein degraders focused on nuclear transport proteins, aiming to degrade rather than inhibit oncology targets for improved safety and efficacy.

Funding History

1
Total raised:$8M
Seed$8M

Opportunities

The validated XPO1 target presents a significant opportunity to improve upon existing toxic therapies, potentially expanding into broader cancer indications and earlier treatment lines.
The high interest and investment in the targeted protein degradation field could facilitate partnerships and additional financing.
Addressing refractory cancers represents a large market with urgent unmet need and potential for accelerated regulatory pathways.

Risk Factors

Lead candidate TSM74 carries translational risk, as promising preclinical results may not replicate in human clinical trials.
The company faces intense competition in both the XPO1 inhibitor and protein degrader spaces from larger, better-funded entities.
As a pre-revenue, private company, Telo is dependent on securing future funding rounds in a challenging capital environment to continue operations.

Competitive Landscape

Telo competes directly with companies developing next-generation XPO1 inhibitors (e.g., non-covalent inhibitors) and other biotechs in the targeted protein degradation space, such as Arvinas, Kymera Therapeutics, and Nurix Therapeutics, which have broader platforms and later-stage pipelines. It also competes with the marketed therapy selinexor (Karyopharm Therapeutics) and must demonstrate a superior profile to gain market share.

More companies in Small Molecule Drugs →More companies in United States →